Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...

As part of its commitment to transparency, DMD published its 2024 Impact Report, detailing certified environmental performance, governance practices, and operational results aligned with SASB ...

Sarepta Therapeutics said it will update its prescribing information for Elevidys ® (delandistrogene moxeparvovec-rokl) after acknowledging the sudden death of a patient with Duchenne muscular ...

A successful Phase 3 trial and a public offeringof stock boosted prospects for this company to receive approval for an ...